FGD3 and breast carcinoma: Interestingly, according to multivariate analysis, our results indicate that FGD3 expression represents an independent predictor of clinical outcome in breast cancer patients in terms of OS, second only to the AJCC stage, in agreement with the literature [9,14,26].